Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Jpn J Ophthalmol ; 67(3): 346-352, 2023 May.
Article in English | MEDLINE | ID: mdl-37067634

ABSTRACT

PURPOSE: To determine the status of visual impairment certification in Japan in the fiscal year 2019 and the impact of revising the criteria for visual impairment certification implemented in 2018. STUDY DESIGN: Observational cross-sectional study. METHODS: We requested welfare offices throughout Japan to submit data of age, sex, causative diseases, and visual impairment grades for newly certified visually impaired individuals aged ≥ 18 years during the fiscal year 2019. The certification was based on criteria of the Act on Welfare of Physically Disabled Persons. RESULTS: Altogether, data were collected for 16,504 newly certified visually impaired individuals. The most common age group was 80-89 years (29.6%), followed by 70-79 (28.2%) and 60-69 (15.3%) years. The most common causative disease was glaucoma (40.7%), followed by retinitis pigmentosa (13.0%), diabetic retinopathy (10.2%), and macular degeneration (9.1%). The most common impairment grade was grade 2 (40.8%), followed by 5 (21.2%) and 1 (17.0%). Compared to the fiscal year 2015, there was a considerable increase in the number of individuals certified with glaucoma in the fiscal year 2019. Moreover, there was a significant increase in the number of individuals with certified grades 1 and 2 visual impairment, with a decrease in the number of individuals with certified grade 6 visual impairment. CONCLUSION: The changes revealed in this study were primarily due to the revised certification criteria implemented in July 2018, indicating that it is important to review the certification criteria and to repeat surveys similar to the present study.


Subject(s)
Glaucoma , Vision, Low , Visually Impaired Persons , Adolescent , Aged, 80 and over , Humans , Blindness/etiology , Certification , Cross-Sectional Studies , Glaucoma/diagnosis , Glaucoma/epidemiology , Glaucoma/complications , Japan/epidemiology , Vision, Low/epidemiology
2.
Acta Med Okayama ; 75(3): 391-395, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34176945

ABSTRACT

A 58-year-old Japanese man underwent vitrectomy for rhegmatogenous retinal detachment (RRD) in 2002. Twelve years later, optical coherence tomography revealed the development of a lamellar macular hole; the visual acuity was 20/200. Two years later, because metamorphopsia and the foveal retina thinning were aggravated, epiretinal proliferation embedding was performed to restore the foveal structure by transplanting glial cells to the foveal cavity. The patient was followed-up for 4 years, and his macular morphology and visual acuity (20/66) improved. No complications occurred. This appears to be the first report of epiretinal proliferation embedding for a lamellar macular hole post-RRD repair.


Subject(s)
Cell Proliferation , Epiretinal Membrane/surgery , Retinal Perforations/surgery , Humans , Male , Middle Aged , Recurrence , Retinal Detachment/surgery , Retinal Perforations/diagnostic imaging , Retinal Perforations/pathology , Tomography, Optical Coherence , Vitrectomy/adverse effects
3.
PLoS One ; 13(9): e0204363, 2018.
Article in English | MEDLINE | ID: mdl-30235323

ABSTRACT

PURPOSE: To compare the success rates of eye drop instillation in the sitting position and supine position among Japanese patients with ocular diseases (cataract, glaucoma, or retinal and vitreous diseases). METHODS: Patients who were hospitalized in Okayama University Hospital for eye surgery were studied. Instillation procedures of each patient in both the sitting and supine positions were recorded using a video camera at the time of instillation. We defined "success" when one drop fell accurately onto the ocular surface at the first attempt. Instillation of two or more drops, drops delivered to a site other than the eye surface, and touching the eyelashes, eyelids, or conjunctiva with the tip of the eye drop bottle were regarded as "failure". We excluded patients with vision below counting finger. RESULTS: One-hundred and two patients (54 males and 58 females, aged 70.2 ± 12.3 years) with ocular disease who were hospitalized for surgery (cataract: 61.8%, glaucoma: 15.7%, retinal and vitreous diseases: 22.5%) were included in this prospective observational study. The mean duration of eye drop use was 3.1 ± 5.2 years. The success rate of eye drop instillation was significantly higher in the supine position than in the sitting position (64.7% vs. 50%, P = 0.0039). The mean age was significantly higher in the failure group than in the success group (74.0 ± 11.5 vs. 67.7 ± 12.4 years, P = 0.0085) for the sitting position, but not significantly different for the supine position (72.3 ± 12.9 vs. 70.1 ± 12.0 years, P = 0.3849). No significant differences in mean duration of drop use, mean corrected VA, and mean spherical equivalent refraction were observed between success and failure groups, for both sitting and supine positions. CONCLUSIONS: In the present study, the success rate of eye drop instillation was significantly higher when applied in the supine position than in the sitting position.


Subject(s)
Ophthalmic Solutions/administration & dosage , Sitting Position , Adult , Age Factors , Aged , Aged, 80 and over , Eye Diseases/drug therapy , Female , Hospitalization , Humans , Male , Middle Aged , Ophthalmic Solutions/therapeutic use , Supine Position , Young Adult
4.
PLoS One ; 12(8): e0184096, 2017.
Article in English | MEDLINE | ID: mdl-28850613

ABSTRACT

We examined the effectiveness of trabeculectomy in decreasing the slope of mean deviation (MD) in Japanese patients with progressive normal-tension glaucoma (NTG) at low intraocular pressure (IOP) levels. The charts of patients who had undergone initial trabeculectomy with adjunctive mitomycin C for progressive NTG with medically controlled IOP < 15 mmHg in 2010-2013 were retrospectively reviewed. Seventeen eyes of 13 NTG patients who had undergone at least 5 times of visual field (VF) examinations in both of preoperatively and postoperatively with postoperative follow-up of ≥ 2 years were enrolled. Preoperative and postoperative MD slopes were compared to evaluate the effectiveness of trabeculectomy in slowing progression of VF. Mean IOP (8.1 ± 2.9 mmHg) and number of IOP-lowering medications (0.8 ± 1.5) were significantly lower postoperatively than preoperatively (13.9 ± 0.9 mmHg; P < 0.001 and 3.0± 0.4; P < 0.0001). In total, 91.7% of eyes with single-digit IOP postoperatively showed improvement in MD slope, whereas only 20.0% of eyes with IOP ≥ 10 mmHg postoperatively showed the improvement. Three eyes (17.6%) showed a decrease in visual acuity (VA) of ≥ 0.1 unit; this group had a lower mean postoperative IOP (6.0 ± 1.0 vs. 8.6 ± 3.0 mmHg; P = 0.1717) and a higher mean IOP reduction rate (56.2 vs. 38.5%; P = 0.8296) than eyes with a VA decrease of < 0.1 unit or no change. Thus, in this analysis of Japanese NTG patients with medically controlled IOP < 15 mmHg, achieving an IOP < 10 mmHg with trabeculectomy was beneficial for reducing the VF progression rate in progressive NTG at low IOP levels. However, an IOP < 7 mmHg by surgery would be required careful attention to VA decline.


Subject(s)
Intraocular Pressure/physiology , Low Tension Glaucoma/surgery , Trabeculectomy , Visual Fields/physiology , Aged , Aged, 80 and over , Disease Progression , Female , Humans , Japan , Low Tension Glaucoma/physiopathology , Male , Middle Aged , Mitomycin/therapeutic use , Retrospective Studies , Tonometry, Ocular , Treatment Outcome , Visual Acuity/physiology
5.
PLoS One ; 12(7): e0181550, 2017.
Article in English | MEDLINE | ID: mdl-28727804

ABSTRACT

For primary open angle glaucoma (POAG), laser treatment or surgery is used when the target intraocular pressure (IOP) cannot be achieved by pharmacological agents, such as prostaglandin (PG) analogs; these drugs also have varied effects. We retrospectively reviewed the medical records of 74 POAG patients (74 eyes) whose IOP was inadequately controlled by PG analogs (bimatoprost [13 eyes], latanoprost [34 eyes], tafluprost [11 eyes], and travoprost [16 eyes]) and underwent primary trabeculectomy. The proportion of patients with no recurrent IOP elevation within 24 months post-trabeculectomy was significantly (P < 0.001) lower in the bimatoprost group (31.3%) than in the latanoprost (83.2%), tafluprost (45.5%), or travoprost groups (65.6%). Deepening of the upper eyelid sulcus (DUES) was observed before trabeculectomy in 18 of 74 eyes (24.3%) treated with bimatoprost (9 eyes; 50.0%), latanoprost (3 eyes; 16.7%), tafluprost (1 eye; 5.5%) and travoprost (5 eyes; 27.8%). The proportion of patients with no recurrent IOP elevation up to 24 months post-trabeculectomy was significantly (P < 0.0001) lower in the DUES(+) group (34.7%) than in the DUES(-) group (74.3%). Multivariate stepwise logistic regression analysis, with no recurrent IOP elevation used as dependent variable, and bimatoprost, latanoprost, travoprost, tafluprost, ß-blocker, carbonic anhydrase inhibitor, brimonidine, gender, age, preoperative IOP, mean deviation, duration of PG analog use before surgery, and the number of ophthalmic solutions used as independent variables, identified only bimatoprost as a significant independent factor (P = 0.0368). Thus, the outcome of trabeculectomy varied depending on the PG analog used preoperatively, and bimatoprost use was associated with a high risk of recurrent IOP elevation up to 2 years post-trabeculectomy. This may indicate that the incidence of DUES differed with the PG analog used. Patients with glaucoma who are treated with bimatoprost should be monitored for DUES, and when these patients undergo trabeculectomy, the postoperative course of IOP should be followed carefully.


Subject(s)
Glaucoma/drug therapy , Glaucoma/surgery , Preoperative Care , Prostaglandins, Synthetic/administration & dosage , Trabeculectomy , Aged , Analysis of Variance , Bimatoprost/administration & dosage , Female , Glaucoma/physiopathology , Humans , Intraocular Pressure/drug effects , Latanoprost , Logistic Models , Male , Middle Aged , Multivariate Analysis , Prostaglandins F/administration & dosage , Prostaglandins F, Synthetic/administration & dosage , Recurrence , Retrospective Studies , Travoprost/administration & dosage , Treatment Outcome
6.
Jpn J Clin Oncol ; 45(12): 1139-45, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26438540

ABSTRACT

OBJECTIVE: Second primary malignancies have become the leading cause of death in retinoblastoma survivors. Although osteosarcoma is the most common second malignancy, little is known about its clinical and therapeutic features. METHODS: We retrospectively reviewed a database of patients with retinoblastoma and osteosarcoma occurring as a second malignancy between 1964 and 2010 at the National Cancer Center Hospital of Japan. RESULTS: Among 857 patients with retinoblastoma registered in the database, 10 (1.1%) developed osteosarcoma as a second malignancy. The median age at the onset of retinoblastoma was 3 months, being bilateral in nine patients and unilateral in one. Systemic chemoreduction was performed in three patients and intra-arterial chemotherapy in six; all patients received external beam radiotherapy. The median age at the onset of second primary osteosarcoma was 11.2 years; four were radiation-related and six were located in an extremity. Among five patients treated at our institute, four patients with tumors on an extremity were treated by wide resection with neoadjuvant and adjuvant chemotherapy. Three of these four patients (75%) were good responders to high-dose methotrexate-based multi-agent chemotherapy and survived with no evidence of disease (median follow-up period, 17.3 years). One patient whose temporal bone was affected underwent radiotherapy with chemotherapy but died after local recurrence. CONCLUSIONS: The clinical outcomes of second primary osteosarcoma in an extremity occurring in retinoblastoma survivors may be more favorable than those of conventional osteosarcoma. Early diagnosis of radiation-related osteosarcoma arising in the craniofacial region should be made at a stage where complete resection is possible.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Neoplasms, Second Primary/diagnosis , Neoplasms, Second Primary/therapy , Osteosarcoma/diagnosis , Osteosarcoma/therapy , Retinal Neoplasms/pathology , Retinoblastoma/pathology , Survivors , Adolescent , Adult , Age of Onset , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Chemotherapy, Adjuvant , Child , Extremities/surgery , Female , Genetic Predisposition to Disease , Humans , Infant , Infusions, Intra-Arterial , Japan/epidemiology , Male , Methotrexate/administration & dosage , Neoadjuvant Therapy/methods , Neoplasms, Second Primary/epidemiology , Osteosarcoma/epidemiology , Radiotherapy, Adjuvant , Retrospective Studies , Risk Factors
7.
Jpn J Ophthalmol ; 59(3): 164-72, 2015 May.
Article in English | MEDLINE | ID: mdl-25808017

ABSTRACT

PURPOSE: To investigate the safety and efficacy of intravitreal injection of melphalan for retinoblastoma. METHODS: A retrospective chart review of all patients who were administered intravitreal injections of melphalan for retinoblastoma between 1990 and 2011. A total of 264 eyes of 250 patients were included. All ocular adverse events, systemic prognosis, ocular prognosis, and visual acuity were investigated. RESULTS: The total number of intravitreal injections administered was 1,067; each eye received between one and 25 injections. A postoperative subconjunctival tumor developed in one eye. None of the eyes suffered infections or uveitis, and all other adverse events including chorioretinal atrophy displayed incidences of less than 1.5 %. At 5 postoperative years, the cumulative incidence of cataract surgery was 3.1 % among the eyes that were treated without ocular hyperthermia. Distant metastasis or intracranial invasion occurred in 11 patients, all of whom had high-risk pathological factors for metastasis such as optic nerve invasion, but refused to receive adjuvant chemotherapy. Sixty-eight percent of the eyes achieved complete vitreous seed remission, but recurrence occurred in 19 % of these eyes after 10.0 ± 4.9 months. In addition, 47 and 27 % of the eyes without primary macular tumors retained visual acuity of >0.5 and >1.0, respectively. CONCLUSIONS: The risk of extraocular tumor spreading following intravitreal injections is low, and other adverse events are rare. Sixty-eight percent of the treated eyes achieved complete vitreous seed remission, and about half of them retained practical levels of vision. The intravitreal injection of melphalan is a safe and effective treatment for vitreous seeds.


Subject(s)
Antineoplastic Agents, Alkylating/therapeutic use , Melphalan/therapeutic use , Retinal Neoplasms/drug therapy , Retinoblastoma/drug therapy , Adolescent , Child , Child, Preschool , Female , Humans , Infant , Intravitreal Injections , Male , Neoplasm Recurrence, Local , Neoplasm Seeding , Retinal Neoplasms/pathology , Retinoblastoma/pathology , Retrospective Studies , Vitreous Body/pathology , Young Adult
8.
SAGE Open Med ; 3: 2050312115590425, 2015.
Article in English | MEDLINE | ID: mdl-26770789

ABSTRACT

OBJECTIVE: This study investigates the influence of personal characteristics and health-related variables on the care dependency status among elderly in-patients with clinically diagnosed Alzheimer's disease in two countries. METHODS: A descriptive cross-cultural survey was administered to a convenience sample of 137 elderly in-patients. Patients were recruited from a hospital in Japan (N = 77) and from a nursing home in the Netherlands (N = 60). RESULTS: In both countries, almost all participants are assessed on the severity level of care dependency in the range of "completely care dependent" (Japan: 35.1%; the Netherlands: 20.0%), or "to a great extent care dependent" (Japan: 24.7%; the Netherlands: 45.0%), to "partially care dependent" (Japan: 22.1%; the Netherlands: 21.7%). CONCLUSION: This study demonstrates that there is no interdependence between the severity level of care dependency and personal characteristics of patients with Alzheimer's disease in both countries. Regarding the interplay of health-related variables on the severity level of care dependency, a difference was found between countries.

9.
Jpn J Ophthalmol ; 56(4): 401-6, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22669350

ABSTRACT

PURPOSE: To investigate the seasonal variations in myopia progression and axial elongation in Japanese children. METHODS: Ninety-two children who were enrolled in a myopia-control trial and wearing single vision or progressive addition lenses were included in the analyses (mean ± SD age 11.4 ± 1.7 years, mean spherical equivalent refractive error -4.40 ± 1.38 D). Refractive error and axial length were measured every 6 months for 1.5 years by non-cycloplegic autorefraction and partial coherence interferometer, respectively. Myopia progression and axial elongation for each 6-month interval were calculated by subtracting the measure at the end of the interval from that at the beginning. Seasons were classified as summer, winter or others, based on mid-day of the 6-month period between visits. RESULTS: Myopia progression was not significantly influenced by the season. After adjusting study groups (type of spectacles), years and age at the baseline, the mean (±SE) myopia progression was 0.35 ± 0.04 D for summer, 0.28 ± 0.06 D for winter and 0.38 ± 0.04 D for the others. In contrast, axial elongation was significantly influenced by the season, and the mean axial elongation was 0.137 ± 0.010 mm for summer, 0.170 ± 0.013 mm for winter and 0.163 ± 0.008 mm for the others. The seasonal variation in axial elongation, however, was smaller than that previously reported overseas. CONCLUSIONS: In Japanese children myopia progression did not slow in summer. Although axial elongation slightly decreased in summer, myopia progression seems to be fairly stable throughout the year.


Subject(s)
Axial Length, Eye/pathology , Eyeglasses , Myopia/physiopathology , Myopia/therapy , Seasons , Adolescent , Asian People , Child , Cross-Over Studies , Disease Progression , Double-Blind Method , Female , Humans , Japan , Male , Prospective Studies
10.
Endocr J ; 57(12): 1017-22, 2010.
Article in English | MEDLINE | ID: mdl-20938101

ABSTRACT

The prevalence of menstrual disturbances, including secondary amenorrhea, hypomenorrhea, oligomenorrhea, hypermenorrhea, polymenorrhea and irregular menstrual cycle were prospectively examined in 586 patients with hyperthyroidism due to Graves' disease, 111 with hypothyroidism, 558 with euthyroid chronic thyroiditis, 202 with painless thyroiditis and 595 with thyroid tumor. In the overall patient group, the prevalence did not different from that in 105 healthy controls. However, patients with severe hyperthyroidism showed a higher prevalence of secondary amenorrhea (2.5%) and hypomenorrhea (3.7%) than those (0.2% and 0.9%, respectively) with mild or moderate hyperthyroidism. Moreover, patients with severe hypothyroidism had a higher prevalence (34.8%) of menstrual disturbances than mild-moderate cases (10.2%). Menstrual disturbances in thyroid dysfunction were less frequent than previously thought.


Subject(s)
Menstruation Disturbances/epidemiology , Thyroid Diseases/complications , Adult , Amenorrhea/complications , Amenorrhea/epidemiology , Female , Graves Disease/complications , Humans , Hyperthyroidism/complications , Hypothyroidism/complications , Menstruation Disturbances/complications , Middle Aged , Oligomenorrhea/complications , Oligomenorrhea/epidemiology , Prospective Studies , Thyroid Neoplasms/complications , Thyroiditis/complications
SELECTION OF CITATIONS
SEARCH DETAIL